
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded capsule containing albuterol, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing albuterol are listed in tablet and syrup forms for use by mouth, and as inhalation aerosols, inhalation solutions and inhalation powders. No finished albuterol product of any kind is listed in capsule form.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Albuterol is a short-acting beta2-agonist bronchodilator used by inhalation and by mouth; compounded preparations require a prescription and are not FDA-approved.
Albuterol, also called salbutamol, is a bronchodilator. It acts on beta2-adrenergic receptors in the airways, which relaxes the smooth muscle around the breathing tubes. Most manufactured products contain albuterol as albuterol sulfate, the racemic form of the drug. Ventolin HFA inhalation aerosol is FDA-approved to treat or prevent bronchospasm in people 4 and older with reversible obstructive airway disease and to prevent exercise-induced bronchospasm. Albuterol inhalation solution for nebulizers, albuterol tablets and albuterol sulfate syrup are approved to relieve bronchospasm in reversible obstructive airway disease, with age limits that differ by product; powder inhalers are also listed. Extended-release albuterol tablets are listed as discontinued in Drugs@FDA. A prescriber may order albuterol compounded in a form or strength not manufactured. Compounded preparations are not FDA-approved and require a prescription.
The Ventolin HFA label has no boxed warning. Albuterol can cause paradoxical bronchospasm, a sudden, possibly life-threatening worsening of breathing after a dose; stop it and get help. Needing more doses than usual may signal worsening asthma. Albuterol can change pulse rate and blood pressure, cause ECG changes and lower potassium. Use caution with heart disease, high blood pressure, seizure disorders, an overactive thyroid or diabetes. People allergic to any ingredient should not use it. Beta-blockers can block its effect and may cause severe bronchospasm in asthma. Loop or thiazide diuretics can worsen low potassium, digoxin levels can fall, and MAO inhibitors or tricyclic antidepressants, including within two weeks of stopping them, can increase albuterol's effects on blood vessels. There is a pregnancy registry for asthma medicines. LactMed notes inhaled bronchodilators are considered acceptable during breastfeeding. For side effects, talk to your prescriber or pharmacist.
Albuterol preferentially stimulates beta2-adrenergic receptors; activation on airway smooth muscle raises cyclic AMP through adenyl cyclase, activating protein kinase A and lowering intracellular calcium, which relaxes smooth muscle. Beta2 receptors make up 10% to 50% of beta receptors in the human heart, so even selective beta2-agonists may have cardiac effects (label). Systemic levels are low after inhalation; the Ventolin HFA label gives an apparent terminal half-life of about 4.6 hours. After oral tablets, absorption is rapid with peak levels within 2 hours and a half-life of about 5 hours; most of an oral dose is excreted in urine, largely as a metabolite, with 4% in feces. Labeled indications: Ventolin HFA (bronchospasm and exercise-induced bronchospasm, age 4 and older); albuterol inhalation solution, tablets and syrup (relief of bronchospasm in reversible obstructive airway disease). StatPearls describes albuterol as an off-label adjunct for hyperkalemia; that is not an FDA-approved indication. Concomitant use of other oral sympathomimetics is not recommended with albuterol tablets. Dosing per prescriber. Monitor heart rate, blood pressure, potassium and signs of asthma deterioration; the label notes ECG changes such as T wave flattening, QTc prolongation and ST depression with beta-agonists.
Swallow each capsule whole with a glass of water, unless your label says otherwise. Do not crush, chew or open the capsule unless your pharmacist tells you it is safe to do so. Take it at the times shown on your prescription label. If you miss a dose or are unsure how to take it, call the pharmacy.
Capsules are nonaqueous, so under USP <795> they usually carry a beyond-use date of up to 180 days when no other stability data apply. Keep the vial tightly closed at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard any capsules left after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth